Analyst Price Targets — CRBP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 26, 2026 10:42 am | — | H.C. Wainwright | $35.00 | $11.31 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP) |
| August 13, 2026 10:36 am | Graig Suvannavejh | Mizuho Securities | $33.00 | $9.76 | StreetInsider | Corbus Pharmaceuticals (CRBP) PT Lowered to $33 at Mizuho |
| May 22, 2026 11:05 am | Graig Suvannavejh | Mizuho Securities | $44.00 | $12.27 | TheFly | Corbus Pharmaceuticals price target raised to $44 from $40 at Mizuho |
| May 12, 2026 8:04 pm | Maury Raycroft | Jefferies | $33.00 | $11.43 | TheFly | Corbus Pharmaceuticals price target lowered to $33 from $36 at Jefferies |
| October 29, 2025 12:49 pm | — | Mizuho Securities | $39.00 | $17.12 | TheFly | Corbus Pharmaceuticals price target raised to $39 from $32 at Mizuho |
| October 20, 2025 12:32 pm | — | Piper Sandler | $51.00 | $16.86 | TheFly | Corbus Pharmaceuticals price target raised to $51 from $35 at Piper Sandler |
| October 20, 2025 10:56 am | — | H.C. Wainwright | $40.00 | $19.32 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP) |
| December 2, 2024 9:09 am | Biren Amin | Piper Sandler | $35.00 | $17.82 | StreetInsider | Piper Sandler Starts Corbus Pharmaceuticals (CRBP) at Overweight |
| October 21, 2024 6:17 am | Jeff Jones | Oppenheimer | $60.00 | $18.41 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP) |
| September 20, 2024 1:04 pm | Kalpit Patel | B.Riley Financial | $40.00 | $19.51 | StreetInsider | Corbus Pharmaceuticals (CRBP) PT Lowered to $40 at B.Riley |
Latest News for CRBP
Corbus Pharmaceuticals NASDAQ: CRBP reported top-line results from CANYON-1, a Phase 1b trial evaluating CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. The 12-week, placebo-controlled study enrolled 254 patients across 15 U.S. sites, with participants having an average body mass index of approximately 37 and 71% of participants being female.
Clinical-stage biopharmaceutical firm Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) on Monday reported topline results from its CANYON-1 Phase 1b trial evaluating CRB-913 as an obesity treatment.
CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau observed CRB-913 was generally well tolerated with psychiatric adverse events broadly in line with GLP-1 drugs and a favorable emerging GI tolerability profile Data support CRB-913's potential to establish a new class of oral non-incretin obesity medicines Data selected for…
Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT
NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the grant of inducement equity awards outside of the Company's stockholder-approved equity compensation plans to Leonardo Nicacio in connection with his commencement of employment as Chief Medical Officer of the Company. The…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRBP.
U.S. House Trading
No House trades found for CRBP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.